MarketPulse

Attruby

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bridgebio Pharma, Inc.

BridgeBio's Acoramidis Cuts Mortality Risk in Half for Rare Heart Disease

BridgeBio reports acoramidis cuts all-cause mortality 44.7% and cardiovascular mortality 49.3% in ATTR-CM patients at Month 54 versus placebo.
BBIOFDA approvalclinical trial
BenzingaBenzinga··Vandana Singh

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.
PFEBBIOBMRNALNYregulatory approvaldrug development